Comparative Pharmacology
Head-to-head clinical analysis: DACTINOMYCIN versus MUTAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACTINOMYCIN versus MUTAMYCIN.
DACTINOMYCIN vs MUTAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to DNA at guanine-cytosine base pairs, inhibiting RNA synthesis by preventing RNA polymerase elongation, thereby blocking transcription.
Cross-links DNA strands, inhibiting DNA synthesis and function.
Intravenous, 15 mcg/kg (max 500 mcg) daily for 5 days every 3-6 weeks; may repeat every 3 weeks.
20 mg/m² intravenously every 6 to 8 weeks, as a single bolus dose.
None Documented
None Documented
Terminal elimination half-life ≈ 36 hours (range 24–48 h) in adults; prolonged in hepatic impairment.
Terminal half-life: 30-60 minutes; clinically, rapid clearance necessitates IV bolus administration.
Clinical Note
moderateDactinomycin + Digoxin
"Dactinomycin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDactinomycin + Digitoxin
"Dactinomycin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDactinomycin + Deslanoside
"Dactinomycin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDactinomycin + Acetyldigitoxin
"Dactinomycin may decrease the cardiotoxic activities of Acetyldigitoxin."
Primarily biliary/fecal (≈50–60% as unchanged drug); renal excretion is minimal (<10%).
Primarily hepatic metabolism; approximately 10-30% excreted unchanged in urine; small amount in bile.
Category D/X
Category C
Antitumor Antibiotic
Antitumor Antibiotic